Stay updated with breaking news from Biohaven Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Harvest Management LLC lowered its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 3.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,100 shares of the company’s stock after selling 500 shares during the quarter. Biohaven comprises 0.6% of Harvest Management LLC’s holdings, […]
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated...
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular...
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiate
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.